My PhD project focuses on the experimental determination of the oxidation state of KP-1339, a Ruthenium based anti-cancer drug focusing on the hypothesis activation by reduction” of Ru(III) to Ru(II) by means of 3D electron crystallography[1].

Trondl, R. et al. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chem. Sci. 5, 2925–2932 (2014)

I am also interested in all small crystals specially Zeolites that have been challenging for structural determination.

Zeolites and MOFs are great candidate to show the powerful application of the 3D ED.

Please find my recent paper Wennmacher et al., Angewandte Chemie Int. Ed. (2020).

J. T. C. Wennmacher, S. Mahmoudi, P. Rzepka, S. Sik Lee, T. Gruene, V. Paunović, J. A. van Bokhoven, Angew. Chem. Int. Ed. 2022, e202205413; Angew. Chem. 2022, e202205413.